Investment Proposition

TACC3 is a unique cancer target because it helps aggressive tumours survive and spread but is not important in normal adults which creates a rare chance to hit the cancer's foundations with potentially less toxicity than many standard cancer treatments.

Our lead asset, AO-252, is a first-in-class brain penetrant small molecule targeting solid tumours. We are positioned within the high-growth precision oncology sector, where comparable approved therapies have market sizes exceeding US$20 billion.

AO-252 is currently in a Phase I trial in the United States, where it has already demonstrated early signals of efficacy, including tumour reductions of up to 33% in patients having had various other treatments. Importantly AO-252 has a benign safety profile and a patient-friendly oral delivery format. The Company is now planning to initiate dose expansion studies, with the strategic objective of advancing AO-252 into a registration-grade trial to expedite the route to market authorisation.

In addition to our lead clinical asset, we are assessing our STAT-6 program utilising siRNA technology. This dual-program strategy targets significant unmet needs in both oncology and immunology, providing a balanced portfolio and multiple pathways to value creation.

The Company is led by an experienced board and management team with a track record in drug development and successful exits.

2026 represents a pivotal year for the Group, with the commencement of dose expansion studies with the expectation of material data readouts by the fourth quarter. These milestones are intended to drive shareholder value and facilitate strategic partnership discussions with global pharmaceutical companies.